{
    "q": [
        {
            "docid": "2412761_2",
            "document": "Dopaminergic . Dopaminergic means \"related to dopamine\" (literally, \"working on dopamine\"), dopamine being a common neurotransmitter. Dopaminergic substances or actions increase dopamine-related activity in the brain. Dopaminergic brain structures facilitate dopamine-related activity. For example, certain proteins such as the dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT), and dopamine receptors can be classified as dopaminergic, and neurons that synthesize or contain dopamine and synapses with dopamine receptors in them may also be labeled as \"dopaminergic\". Enzymes that regulate the biosynthesis or metabolism of dopamine such as aromatic L-amino acid decarboxylase or DOPA decarboxylase, monoamine oxidase (MAO), and catechol \"O\"-methyl transferase (COMT) may be referred to as \"dopaminergic\" as well. Also, any endogenous or exogenous chemical substance that acts to affect dopamine receptors or dopamine release through indirect actions (for example, on neurons that synapse onto neurons that release dopamine or express dopamine receptors) can also be said to have \"dopaminergic\" effects, two prominent examples being opioids, which enhance dopamine release indirectly in the reward pathways, and some substituted amphetamines, which enhance dopamine release directly by binding to and inhibiting VMAT.",
            "score": 256.2685217857361
        },
        {
            "docid": "48548_15",
            "document": "Dopamine . Dopamine exerts its effects by binding to and activating cell surface receptors. In humans, dopamine has a high binding affinity at dopamine receptors and human trace amine-associated receptor 1 (hTAAR1). In mammals, five subtypes of dopamine receptors have been identified, labeled from D1 to D5. All of them function as metabotropic, G protein-coupled receptors, meaning that they exert their effects via a complex second messenger system. These receptors can be divided into two families, known as D1-like and D2-like. For receptors located on neurons in the nervous system, the ultimate effect of D1-like activation (D1 and D5) can be excitation (via opening of sodium channels) or inhibition (via opening of potassium channels); the ultimate effect of D2-like activation (D2, D3, and D4) is usually inhibition of the target neuron. Consequently, it is incorrect to describe dopamine itself as either excitatory or inhibitory: its effect on a target neuron depends on which types of receptors are present on the membrane of that neuron and on the internal responses of that neuron to the second messenger cAMP. D1 receptors are the most numerous dopamine receptors in the human nervous system; D2 receptors are next; D3, D4, and D5 receptors are present at significantly lower levels.",
            "score": 360.12039518356323
        },
        {
            "docid": "148980_20",
            "document": "Chlorpromazine . Chlorpromazine is a very effective antagonist of D2 dopamine receptors and similar receptors, such as D3 and D5. Unlike most other drugs of this genre, it also has a high affinity for D1 receptors. Blocking these receptors causes diminished neurotransmitter binding in the forebrain, resulting in many different effects. Dopamine, unable to bind with a receptor, causes a feedback loop that causes dopaminergic neurons to release more dopamine. Therefore, upon first taking the drug, patients will experience an increase in dopaminergic neural activity. Eventually, dopamine production of the neurons will drop substantially and dopamine will be removed from the synaptic cleft. At this point, neural activity decreases greatly; the continual blockade of receptors only compounds this effect.",
            "score": 305.21752095222473
        },
        {
            "docid": "48548_17",
            "document": "Dopamine . Once in the synapse, dopamine binds to and activates dopamine receptors. These can be postsynaptic dopamine receptors, which are located on dendrites (the postsynaptic neuron), or presynaptic autoreceptors (e.g., the Dsh and presynaptic D receptors), which are located on the membrane of an axon terminal (the presynaptic neuron). After the postsynaptic neuron elicits an action potential, dopamine molecules quickly become unbound from their receptors. They are then absorbed back into the presynaptic cell, via reuptake mediated either by the dopamine transporter or by the plasma membrane monoamine transporter. Once back in the cytosol, dopamine can either be broken down by a monoamine oxidase or repackaged into vesicles by VMAT2, making it available for future release.",
            "score": 233.58700942993164
        },
        {
            "docid": "5035843_10",
            "document": "Area postrema . The area postrema also has a significant role in the discussion of Parkinson's disease. Drugs that treat Parkinson's disease using dopamine have a strong effect on the area postrema. These drugs stimulate dopamine transmission and attempt to normalize motor functions affected by Parkinson's. This works because nerve cells, in particular, in the basal ganglia, which has a crucial role in the regulation of movement and is the primary site for the pathology of Parkinson's, use dopamine as their neurotransmitter and are activated by medications that increase the concentrations of the dopamine or work to stimulate the dopamine receptors. Dopamine also manages to stimulate the area postrema, since this part of the brain contains a high density of dopamine receptors. The area postrema is very sensitive to changes in blood toxicity and senses the presence of poisonous or dangerous substances in the blood. As a defense mechanism, the area postrema induces vomiting to prevent further intoxication. The high density of dopamine receptors in the area postrema makes it very sensitive to the dopamine-enhancing drugs. Stimulation of the dopamine receptors in the area postrema activates these vomiting centers of the brain; this is why nausea is one of the most common side-effects of antiparkinsonian drugs.",
            "score": 222.15587377548218
        },
        {
            "docid": "48548_2",
            "document": "Dopamine . Dopamine (DA, a contraction of 3,4-dihydroxyphenethylamine) is an organic chemical of the catecholamine and phenethylamine families that plays several important roles in the brain and body. It is an amine synthesized by removing a carboxyl group from a molecule of its precursor chemical L-DOPA, which is synthesized in the brain and kidneys. Dopamine is also synthesized in plants and most animals. In the brain, dopamine functions as a neurotransmitter\u2014a chemical released by neurons (nerve cells) to send signals to other nerve cells. The brain includes several distinct dopamine pathways, one of which plays a major role in the motivational component of reward-motivated behavior. The anticipation of most types of rewards increases the level of dopamine in the brain, and many addictive drugs increase dopamine release or block its reuptake into neurons following release. Other brain dopamine pathways are involved in motor control and in controlling the release of various hormones. These pathways and cell groups form a dopamine system which is neuromodulatory.",
            "score": 219.40644478797913
        },
        {
            "docid": "48548_16",
            "document": "Dopamine . Inside the brain, dopamine functions as a neurotransmitter and neuromodulator, and is controlled by a set of mechanisms common to all monoamine neurotransmitters. After synthesis, dopamine is transported from the cytosol into synaptic vesicles by a solute carrier\u2014a vesicular monoamine transporter, VMAT2. Dopamine is stored in these vesicles until it is ejected into the synaptic cleft. In most cases, the release of dopamine occurs through a process called exocytosis which is caused by action potentials, but it can also be caused by the activity of an intracellular trace amine-associated receptor, TAAR1. TAAR1 is a high-affinity receptor for dopamine, trace amines, and certain substituted amphetamines that is located along membranes in the intracellular milieu of the presynaptic cell; activation of the receptor can regulate dopamine signaling by inducing dopamine reuptake inhibition and efflux as well as by inhibiting neuronal firing through a diverse set of mechanisms.",
            "score": 241.607768535614
        },
        {
            "docid": "14760882_3",
            "document": "PPP1R1B . Midbrain dopaminergic neurons play a critical role in multiple brain functions, and abnormal signaling through dopaminergic pathways has been implicated in several major neurologic and psychiatric disorders. One well studied target for the actions of dopamine is DARPP32. In the densely dopamine- and glutamate-innervated rat caudate-putamen, DARPP32 is expressed in medium-sized spiny neurons that also express dopamine D1 receptors. The function of DARPP32 seems to be regulated by receptor stimulation. Both dopaminergic and glutamatergic (NMDA) receptor stimulation regulate the extent of DARPP32 phosphorylation, but in opposite directions. Dopamine D1 receptor stimulation enhances cAMP formation, resulting in the phosphorylation of DARPP32; (this is disputed by more recent research that claims cAMP signaling induces dephosphorylation of DARPP32) phosphorylated DARPP32 is a potent protein phosphatase-1 (PPP1CA) inhibitor. NMDA receptor stimulation elevates intracellular calcium, which leads to activation of calcineurin and dephosphorylation of phospho-DARPP32, thereby reducing the phosphatase-1 inhibitory activity of DARPP32. DARPP-32 is critical for dopamine dependent striatal synaptic plasticity, possibly by serving as a dopamine-dependent gating mechanism for calcium/CaMKII signaling. It has been predicted that DARPP-32, in conjunction with ARPP-21, could also be involved in setting-up of eligibility trace-like temporal window for striatal postsynaptic signaling.",
            "score": 252.85866749286652
        },
        {
            "docid": "14131548_4",
            "document": "Dopamine receptor D1 . The D subtype of the dopamine receptor is the most abundant dopamine receptor in the central nervous system. This G-protein coupled receptor is Gs/a coupled and indirectly activates cyclic AMP-dependent protein kinase, stimulating the neuron. D receptors regulate neuronal growth and development, mediate some behavioral responses, and modulate dopamine receptor D-mediated events. Alternative transcription initiation sites result in two transcript variants of the gene. D1-D2 dopamine receptor heteromer formation is observed.",
            "score": 316.5921642780304
        },
        {
            "docid": "599614_24",
            "document": "Dopamine hypothesis of schizophrenia . Research has shown the importance of glutamate receptors, specifically N-methyl-D-aspartate receptors (NMDARs), in addition to dopamine in the etiology of schizophrenia. Mice with only 5% of the normal levels of NMDAR\u2019s expressed schizophrenic like behaviors seen in animal models of schizophrenia while mice with 100% of NMDAR\u2019s behaved normally. Schizophrenic behavior in low NMDAR mice has been effectively treated with antipsychotics that lower dopamine. NMDAR\u2019s and dopamine receptors in the prefrontal cortex are associated with the cognitive impairments and working memory deficits commonly seen in schizophrenia. Rats that have been given a NMDAR antagonist exhibit a significant decrease in performance on cognitive tasks. Rats given a dopamine antagonist (antipsychotic) experience a reversal of the negative effects of the NMDAR antagonist. Glutamate imbalances appear to cause abnormal functioning in dopamine. When levels of glutamate are low dopamine is overactive and results in the expression schizophrenic symptoms.",
            "score": 191.79385781288147
        },
        {
            "docid": "57441533_6",
            "document": "D. James Surmeier . Around the same time, using multi-disciplinary approaches, his lab provided a possible explanation for the striatopallidal pathway dysfunction associated with Parkinson\u2019s disease and dopamine depletion by demonstrating a calcium channel (CaV1.3) dependent loss of excitatory synapses in the indirect pathway spiny neurons in a rodent model of the disease. Loss of striatal dopamine results in decreased M4 (muscarinic acetylcholine auto receptor) signaling associated with up-regulation of RGS4 (regulators of G protein signaling) expression in cholinergic neurons, culminating in increased cholinergic tone. Following dopamine depletion leading to increase in striatal acetylcholine levels, M1 muscarinic receptor activation in the indirect pathway spiny neurons results in down-regulation of dendritic potassium channels, Kir2 , elevating the dendritic excitability and consequently the impact of synaptically released glutamate in these neurons. Thus, work from Surmeier's lab suggests that not only dopamine but acetylcholine also has differential effects on striatal projection neurons furthering the idea that striatal dopamine/acetylcholine balance is a potential target for therapeutic intervention in diseases marked by striatal dysfunction and sheds light on how striatal neurons and circuits both change and adapt in response to disease states.",
            "score": 255.57517075538635
        },
        {
            "docid": "39182600_11",
            "document": "Heterosynaptic plasticity . Heterosynaptic plasticity is not solely restricted to serotonin. Dopamine has also been shown to act in a neuro modulatory fashion. Much like the serotonin receptors in \"Aplysia,\" dopamine receptors are G-protein-coupled receptors that activate cAMP production. This process, however, is important for the storage of memories in \"mammals,\" while serotonin's occurs in invertebrates. Within dopaminergic and GABAergic terminals, the neuromodulator dopamine is released via heterosynaptic plasticity. Commonly, this plasticity leads to long-term depression, LTD, mediated by dopamine D1 class receptors. These receptors' activation is required to create LTD and modulate its magnitude. Further research on dopamine's role in neuromodulation is also underway. Experiments performed at the University of Pittsburgh looked at the parallel projects of dopaminergic and GABAergic terminals from the ventral tegmental area to the nucleus accumbens core (NAcCo) in rats. Within these parallel projections, scientists discovered that the release of dopamine heterosynaptically triggers LTD at these synapses. Concluding, dopamine is not just a neuromodulator but can also trigger synaptic plasticity independently in neurons. Therefore, heterosynaptic dopamine signaling in mammals can be best represented by dopamine's biological functions of mediating, as well as independently triggering, changes in synaptic plasticity.",
            "score": 225.01793026924133
        },
        {
            "docid": "716908_23",
            "document": "Ventral tegmental area . The nucleus accumbens and the ventral tegmental area are the primary sites where addictive drugs act. The following are commonly considered to be addictive: heroin, cocaine, alcohol, opiates, nicotine, cannabinoids, amphetamine, and their synthetic analogs. These drugs alter the neuromodulatory influence of dopamine on the processing of reinforcement signals by prolonging the action of dopamine in the nucleus accumbens or by stimulating the activation of neurons there and also in the VTA. The most common drugs of abuse stimulate the release of dopamine, which creates both their rewarding and the psychomotor effects. Compulsive drug-taking behaviors are a result of the permanent functional changes in the mesolimbic dopamine system arising from repetitive dopamine stimulation. Molecular and cellular adaptations are responsible for a sensitized dopamine activity in the VTA and along the mesolimbic dopamine projection in response to drug abuse. In the VTA of addicted individuals, the activity of the dopamine-synthesizing enzyme tyrosine hydroxylase increases, as does the ability of these neurons to respond to excitatory inputs. The latter effect is secondary to increases in the activity of the transcription factor CREB and the up regulation of GluR1, an important subunit of AMPA receptors for glutamate. These alterations in neural processing could account for the waning influence of adaptive emotional signals in the operation of decision making faculties as drug-seeking and drug-taking behaviors become habitual and compulsive.",
            "score": 259.89955377578735
        },
        {
            "docid": "8582684_26",
            "document": "Reward system . Addictive drugs and behaviors are rewarding and reinforcing (i.e., are \"addictive\") due to their effects on the dopamine reward pathway. The lateral hypothalamus and medial forebrain bundle has been the most-frequently-studied brain-stimulation reward site, particularly in studies of the effects of drugs on brain stimulation reward. The neurotransmitter system that has been most-clearly identified with the habit-forming actions of drugs-of-abuse is the mesolimbic dopamine system, with its efferent targets in the nucleus accumbens and its local GABAergic afferents. The reward-relevant actions of amphetamine and cocaine are in the dopaminergic synapses of the nucleus accumbens and perhaps the medial prefrontal cortex. Rats also learn to lever-press for cocaine injections into the medial prefrontal cortex, which works by increasing dopamine turnover in the nucleus accumbens. Nicotine infused directly into the nucleus accumbens also enhances local dopamine release, presumably by a presynaptic action on the dopaminergic terminals of this region. Nicotinic receptors localize to dopaminergic cell bodies and local nicotine injections increase dopaminergic cell firing that is critical for nicotinic reward. Some additional habit-forming drugs are also likely to decrease the output of medium spiny neurons as a consequence, despite activating dopaminergic projections. For opiates, the lowest-threshold site for reward effects involves actions on GABAergic neurons in the ventral tegmental area, a secondary site of opiate-rewarding actions on medium spiny output neurons of the nucleus accumbens. Thus GABAergic afferents to the mesolimbic dopamine neurons (primary substrate of opiate reward), the mesolimbic dopamine neurons themselves (primary substrate of psychomotor stimulant reward), and GABAergic efferents to the mesolimbic dopamine neurons (a secondary site of opiate reward) form the core of currently characterized drug-reward circuitry.",
            "score": 258.6340754032135
        },
        {
            "docid": "3987386_6",
            "document": "Pramipexole . Parkinson's disease is a neurodegenerative disease affecting the substantia nigra, a component of the basal ganglia. The substantia nigra has a high quantity of dopaminergic neurons, which are nerve cells that release the neurotransmitter known as dopamine. When dopamine is released, it may activate dopamine receptors in the striatum, which is another component of the basal ganglia. When neurons of the substantia nigra deteriorate in Parkinson's disease, the striatum no longer properly receives dopamine signals. As a result, the basal ganglia can no longer regulate body movement effectively and motor function becomes impaired. By acting as an agonist for the D, D, and D dopamine receptors, pramipexole may directly stimulate the underfunctioning dopamine receptors in the striatum, thereby restoring the dopamine signals needed for proper functioning of the basal ganglia.",
            "score": 243.17086720466614
        },
        {
            "docid": "12134485_8",
            "document": "Nuclear receptor related-1 protein . Studies have shown that heterozygous knockout mice for the NURR1 gene demonstrate reduced dopamine release. Initially this was compensated for by a decrease in the rate of dopamine reuptake; however, over time this reuptake could not make up for the reduced amount of dopamine being released. Coupled with the loss of dopamine receptor neurons, this can result in the onset of symptoms for Parkinson\u2019s Disease.",
            "score": 216.57492685317993
        },
        {
            "docid": "20806653_5",
            "document": "Dopamine dysregulation syndrome . Parkinson's disease is a common neurological disorder characterized by a degeneration of dopamine neurons in the substantia nigra and a loss of dopamine in the putamen. It is described as a motor disease, but it also produces cognitive and behavioral symptoms. The most common treatment is dopamine replacement therapy, which consists in the administration of levodopa (L-Dopa) or dopamine agonists (such as pramipexole or ropinirole) to patients. Dopamine replacement therapy is well known to improve motor symptoms but its effects in cognitive and behavioral symptoms are more complex. Dopamine has been related to the normal learning of stimuli with behavioral and motivational significance, attention, and most importantly the reward system. In accordance with the role of dopamine in reward processing, addictive drugs stimulate dopamine release. Although the exact mechanism has yet to be elucidated, the role of dopamine in the reward system and addiction has been proposed as the origin of DDS. Models of addiction have been used to explain how dopamine replacement therapy produces DDS. One of these models of addiction proposes that over the usage course of a drug there is a habituation to the rewarding that it produces at the initial stages. This habituation is thought to be dopamine mediated. With long-term administration of L-dopa the reward system gets used to it and needs higher quantities. As the user increases drug intake there is a loss of dopaminergic receptors in the striatum which acts in addition to an impairment in goal-direction mental functions to produce an enhancement of sensitization to dopamine therapy. The behavioral and mood symptoms of the syndrome are produced by the dopamine overdose.",
            "score": 205.2232825756073
        },
        {
            "docid": "24514_42",
            "document": "Psychosis . The connection between dopamine and psychosis is generally believed complex. While dopamine receptor D2 suppresses adenylate cyclase activity, the D1 receptor increases it. If D2-blocking drugs are administered the blocked dopamine spills over to the D1 receptors. The increased adenylate cyclase activity affects genetic expression in the nerve cell, which takes time. Hence antipsychotic drugs take a week or two to reduce the symptoms of psychosis. Moreover, newer and equally effective antipsychotic drugs actually block slightly less dopamine in the brain than older drugs whilst also blocking 5-HT2A receptors, suggesting the 'dopamine hypothesis' may be oversimplified. Soyka and colleagues found no evidence of dopaminergic dysfunction in people with alcohol-induced psychosis and Zoldan et al. reported moderately successful use of ondansetron, a 5-HT receptor antagonist, in the treatment of levodopa psychosis in Parkinson's disease patients.",
            "score": 279.962543964386
        },
        {
            "docid": "2870_50",
            "document": "Antipsychotic . Antipsychotic drugs such as haloperidol and chlorpromazine tend to block dopamine D receptors in the dopaminergic pathways of the brain. This means that dopamine released in these pathways has less effect. Excess release of dopamine in the mesolimbic pathway has been linked to psychotic experiences. Decreased dopamine release in the prefrontal cortex, and excess dopamine release in other pathways, are associated with psychotic episodes in schizophrenia and bipolar disorder. In addition to the antagonistic effects of dopamine, antipsychotics (in particular atypical neuroleptics) also antagonize 5-HT receptors. Different alleles of the 5-HT receptor have been associated with schizophrenia and other psychoses, including depression. Higher concentrations of 5-HT receptors in cortical and subcortical areas, in particular in the right caudate nucleus have been historically recorded. This is the same receptor that psychedelic drugs agonize to various degrees, which explains the correlation between psychedelic drugs and schizophrenia.",
            "score": 198.6965401172638
        },
        {
            "docid": "45588500_14",
            "document": "Caffeine-induced anxiety disorder . A receptors are coupled to G proteins which activate adenylate cyclase and some voltage gated Ca channels. A receptors are located in dopamine rich brain regions. A receptor mRNA was found in the same neurons as the dopamine receptor D within the dorsal striatum, nucleus accumbens and tuberculum olfactorium. A receptors are not found in neurons that express the dopamine receptor D receptors and Substance P. Within the striatum, part of the basal ganglia, activation of A receptors by adenosine increases GABA release, an inhibitory neurotransmitter. When caffeine binds to the receptor, less inhibitory neurotransmitter is released, supporting caffeine\u2019s role as a central nervous system stimulant.",
            "score": 227.45499539375305
        },
        {
            "docid": "6685460_6",
            "document": "Low-dose naltrexone . Naltrexone and its active metabolite 6-\u03b2-naltrexol are competitive antagonists at \u03bc-opioid and \u03ba-opioid receptors, and to a lesser extent at \u03b4-opioid receptors. Standard therapeutic doses of naltrexone blocks these receptors, which does two things; it prevents inhibition of GABA receptors (normally, signalling through the GABA receptors inhibits the activity of neurons; many recreational drugs inhibit GABA and thus \"free up\" neuronal activation; preventing inhibition of GABA allows GABA's normal inhibition activity to take place) and it blocks dopamine release (many recreational drugs stimulate dopamine release, which is part of the brain's reward system that creates pleasure).",
            "score": 223.17592334747314
        },
        {
            "docid": "44517156_2",
            "document": "Dopamine therapy . Dopamine therapy is the regulation of levels of the neurotransmitter dopamine through the use of either agonists, or antagonists; and has been used in the treatment of disorders characterized by a dopamine imbalance. Dopamine replacement therapy (DRT) is an effective treatment for patients suffering from decreased levels of dopamine. Often dopamine agonists, compounds that activate dopamine receptors in the absence of that receptor's physiological ligand, the neurotransmitter dopamine, are used in this therapy. DRT has been shown to reduce symptoms and increase lifespan for patients suffering from Parkinson\u2019s Disease. Dopamine regulation plays a critical role in human mental and physical health. The neurons that contain the neurotransmitter are clustered in the midbrain region in an area called the substantia nigra. In Parkinson's patients, the death of dopamine-transmitting neurons in this area leads to abnormal nerve-firing patterns that cause motor problems. Research in patients with schizophrenia indicates abnormalities in dopamine receptor structure and function.",
            "score": 228.95096349716187
        },
        {
            "docid": "5940893_10",
            "document": "Amniotic epithelial cell . Amniotic epithelial cells are able to make and release acetylcholine and catecholamine. They also show gene expression for dopamine receptors and transporters. Because of this, they are also studied by scientists who research effects of new drugs on dopamine receptors and transporters as well as the basic functions including dopamine secretion and uptake. Several scientists have concluded using lab rats with Parkinson's disease that these cells, when transplanted, reversed the effects of the disease by replacing those dopamine releasing neurons that had died and prevented other neurons from being destroyed by the disease. Currently, Parkinson\u2019s disease is treated with dopamine replacement therapy but is not functional with the late progression of the disease and can\u2019t cure the disease. Also, other cells that have been used in the past for transplantation to treat Parkinson\u2019s, such as neural stem cells and embryonic stem cells, are either limited or controversial in their retrieval. Similar positive effects have also been shown in studies involving chickens with neurological disorders.",
            "score": 218.54881846904755
        },
        {
            "docid": "737439_21",
            "document": "Dopamine receptor . Dopamine is the primary neurotransmitter involved in the reward pathway in the brain. Thus, drugs that increase dopamine signaling may produce euphoric effects. Many recreational drugs, such as cocaine and substituted amphetamines, inhibit the dopamine transporter (DAT), the protein responsible for removing dopamine from the neural synapse. When DAT activity is blocked, the synapse floods with dopamine and increases dopaminergic signaling. When this occurs, particularly in the nucleus accumbens, increased D and decreased D receptor signaling mediates the \"rewarding\" stimulus of drug intake.",
            "score": 243.4151291847229
        },
        {
            "docid": "6868_38",
            "document": "Caffeine . Caffeine also causes the release of dopamine in the dorsal striatum and nucleus accumbens core (a substructure within the ventral striatum), but not the nucleus accumbens shell, by antagonizing A receptors in the axon terminal of dopamine neurons and A\u2013A heterodimers (a receptor complex composed of 1 adenosine A receptor and 1 adenosine A receptor) in the axon terminal of glutamate neurons. During chronic caffeine use, caffeine-induced dopamine release within the nucleus accumbens core is markedly reduced due to drug tolerance.",
            "score": 220.25768756866455
        },
        {
            "docid": "8582684_10",
            "document": "Reward system . Two theories exist with regard to the activity of the nucleus accumbens and the generation liking and wanting. The inhibition (or hyperpolarization) hypothesis proposes that the nucleus accumbens exerts tonic inhibitory effects on downstream structures such as the ventral pallidum, hypothalamus or ventral tegmental area, and that in inhibiting in the nucleus accumbens (NAcc), these structures are excited, \"releasing\" reward related behavior. While GABA receptor agonists are capable of eliciting both \"liking\" and \"wanting\" reactions in the nucleus accumbens, glutaminergic inputs from the basolateral amygdala, ventral hippocampus, and medial prefrontal cortex can drive incentive salience. Furthermore, while most studies find that NAcc neurons reduce firing in response to reward, a number of studies find the opposite response. This had lead to the proposal of the disinhibition (or depolarization) hypothesis, that proposes that excitation or NAcc neurons, or at least certain subsets, drives reward related behavior. After nearly 50 years of research on brain-stimulation reward, experts have certified that dozens of sites in the brain will maintain intracranial self-stimulation. Regions include the lateral hypothalamus and medial forebrain bundles, which are especially effective. Stimulation there activates fibers that form the ascending pathways; the ascending pathways include the mesolimbic dopamine pathway, which projects from the ventral tegmental area to the nucleus accumbens. There are several explanations as to why the mesolimbic dopamine pathway is central to circuits mediating reward. First, there is a marked increase in dopamine release from the mesolimbic pathway when animals engage in intracranial self-stimulation. Second, experiments consistently indicate that brain-stimulation reward stimulates the reinforcement of pathways that are normally activated by natural rewards, and drug reward or intracranial self-stimulation can exert more powerful activation of central reward mechanisms because they activate the reward center directly rather than through the peripheral nerves. Third, when animals are administered addictive drugs or engage in naturally rewarding behaviors, such as feeding or sexual activity, there is a marked release of dopamine within the nucleus accumbens. However, dopamine is not the only reward compound in the brain.",
            "score": 200.23763811588287
        },
        {
            "docid": "37691875_20",
            "document": "Addiction-related structural neuroplasticity . Exposure to drugs of abuse elicits LTP at excitatory synapses on VTA dopamine neurons. Excitatory synapses in brain slices from the VTA taken 24 hours after a single cocaine exposure showed an increase in AMPA receptors in comparison to a saline control. Additional LTP could not be induced in these synapses. This is thought to be because the maximal amount of LTP had already been induced by the administration of cocaine. LTP is only seen on the dopamine neurons, not on neighboring GABAergic neurons. This is of interest because the administration of drugs of abuse increases the excitation of VTA dopamine neurons, but does not increase inhibition. Excitatory inputs into the VTA will activate the dopamine neurons 200%, but do not increase activation of GABA neurons which are important in local inhibition.",
            "score": 278.1994960308075
        },
        {
            "docid": "57441533_5",
            "document": "D. James Surmeier . By mid-90s, despite widespread consensus regarding the clinical relevance of striatal dopaminergic signaling, the distribution and seggregation of different classes of dopamine receptors, into either the same or distinct neuronal populations was unclear and remained widely debated. In pioneering experiments, using patch clamp recordings in conjunction with single cell gene profiling through RT-PCR, Surmeier reconciled the seemingly confounding results from anatomical and functional studies by showing that the direct (striatonigral) and indirect pathway (striatopallidal) striatal projection neurons predominantly expressed either the D1 or D2 dopamine receptors. Following this discovery, using pharmacology and spike-timing-dependent plasticity (STDP) protocols in genetically identified D1 or D2 receptor expressing neurons, Surmeier elucidated the distinct roles played by both the receptors in the induction of long-term potentiation and depression at the cortico-striatal synapses. Simultaneously, he also showed that in projection neurons that do not express the D2 receptors, synaptic depression dependent on D2 receptor activation is mediated by D2 receptors in cholinergic neurons, M1 muscarinic receptor activation resulting in reduced calcium channel, CaV1.3 opening in projection neurons and endocannabinoid signaling. Understanding the opposing effects of D1 and D2 receptor signaling and the consequent insights into the dopaminergic modulation of bi-directional synaptic plasticity in the direct and indirect spiny neurons was a conceptual advance that has proven fundamental to understanding striatal function in both behavioral adaptation as well as Parkinson's disease pathology, and continues to provide a foundation for current models of how dopamine controls striatal circuitry.",
            "score": 352.02729082107544
        },
        {
            "docid": "185272_26",
            "document": "Atypical antipsychotic . 5-HT Receptor: When serotonin is released on to postsynaptic 5-HT receptors, the dopamine neuron is inhibited, thus acting as a brake on dopamine release. This brake is disrupted through action of a 5-HT antagonist, which cuts the brake cable, disinhibiting the dopamine neuron, and stimulating dopamine release. The result of this is that dopamine competes with antipsychotic D antagonistic action at D receptors, thereby reducing antagonistic binding there and eliminating or lowering D antagonistic effects in several pathways of the dopamine system. In the nigrostratial pathway, it reduces EPS. In the tuberoinfundibular pathway, it reduces or eliminates prolactin elevation. Dopamine release in the mesolimbic pathway from 5-HT antagonism does not appear to be as robust as in the other pathways of the dopamine system, thereby accounting for why atypical antipsychotics still retain part of their efficacy against the positive symptoms of schizophrenia through their D antagonism. When 5-HT antagonistic agent particles occupy 5-HT receptors in the mesocortical pathway and in the prefrontal cortex, the negative symptoms of schizophrenia, affective symptoms, and cognitive deficits and abnormalities are treated and reduced. Furthermore, 5-HT receptor antagonism blocks the serotonergic excitation of cortical pyramidal cells, reducing glutamate release, which in turn lowers hyperactive dopaminergic D receptor activity in the mesolimbic pathway, reducing or eliminating the positive symptoms of schizophrenia.",
            "score": 220.95801436901093
        },
        {
            "docid": "599614_25",
            "document": "Dopamine hypothesis of schizophrenia . People with Schizophrenia also have a higher incidence of nicotine use than those without schizophrenia. The high rate of use may be a form of self-medication that reduces negative symptoms by increasing the activity of glutamate and lowering the activity of dopamine. Elevated activation in the prefrontal cortex from nicotine use can increase focus and cognitive performance which are impaired in people with schizophrenia. Activation of nicotinic acetylcholine receptors in mice has been shown to increase glutamate levels in the prefrontal cortex and may help to decrease the cognitive deficits seen in schizophrenia. In addition, nicotine is thought to help regulate dopamine release. Nicotine acts as an agonist to nicotinic acetylcholine receptors which then increases the release of dopamine. However, prolonged use of nicotine causes a diminished response to nicotine thus lowering dopamine levels long term. Nicotine use may be higher in people with schizophrenia because it helps to balance levels of glutamate and dopamine in the brain causing a reduction in some negative symptoms.",
            "score": 197.11586773395538
        },
        {
            "docid": "44517156_3",
            "document": "Dopamine therapy . DRT has been used to improve motor skills, impulsivity, and decision making in Parkinson\u2019s patients. In Parkinson\u2019s Disease patients, dopamine deficiencies can be seen in two key areas of the brain: the dorsal frontostriatal circuit, the area responsible for motor skills and task-switching, and the ventral frontostriatal circuit, the area responsible for impulsivity. Impairment in these areas can be treated with dopamine agonists, a group of medications that mimics the ligand dopamine and bonds to dopamine receptors. Other medications that convert into dopamine, as opposed to functioning as dopamine analogs, alleviate the effects of the degeneration of dopamine-producing neurons. One dopamine precursor, Levodopa, was the first drug approved specifically for Parkinson\u2019s disease. DRT increases dopamine in the brain to optimal levels in order to return motor skills, impulsivity, and decision making to normal function. Although DRT can improve motor skills and decision making in patients with mild to severe Parkinson\u2019s Disease, an overdose of dopamine is associated with impaired impulsivity (see next section).",
            "score": 195.3197079896927
        },
        {
            "docid": "27790_28",
            "document": "Schizophrenia . Particular attention has been paid to the function of dopamine in the mesolimbic pathway of the brain. This focus largely resulted from the accidental finding that phenothiazine drugs, which block dopamine function, could reduce psychotic symptoms. It is also supported by the fact that amphetamines, which trigger the release of dopamine, may exacerbate the psychotic symptoms in schizophrenia. The influential dopamine hypothesis of schizophrenia proposed that excessive activation of D receptors was the cause of (the positive symptoms of) schizophrenia. Although postulated for about 20\u00a0years based on the D blockade effect common to all antipsychotics, it was not until the mid-1990s that PET and SPET imaging studies provided supporting evidence. While dopamine D2/D3 receptors are elevated in schizophrenia, the effect size is small, and only evident in medication naive schizophrenics. On the other hand, presynaptic dopamine metabolism and release is elevated despite no difference in dopamine transporter. The altered synthesis of dopamine in the nigrostriatal system have been confirmed in several human studies. Hypoactivity of dopamine D1 receptor activation in the prefrontal cortex has also been observed. The hyperactivity of D2 receptor stimulation and relative hypoactivity of D1 receptor stimulation is thought to contribute to cognitive dysfunction by disrupting signal to noise ratio in cortical microcircuits. The dopamine hypothesis is now thought to be simplistic, partly because newer antipsychotic medication (atypical antipsychotic medication) can be just as effective as older medication (typical antipsychotic medication), but also affects serotonin function and may have slightly less of a dopamine blocking effect.",
            "score": 274.85103952884674
        }
    ],
    "r": [
        {
            "docid": "48548_15",
            "document": "Dopamine . Dopamine exerts its effects by binding to and activating cell surface receptors. In humans, dopamine has a high binding affinity at dopamine receptors and human trace amine-associated receptor 1 (hTAAR1). In mammals, five subtypes of dopamine receptors have been identified, labeled from D1 to D5. All of them function as metabotropic, G protein-coupled receptors, meaning that they exert their effects via a complex second messenger system. These receptors can be divided into two families, known as D1-like and D2-like. For receptors located on neurons in the nervous system, the ultimate effect of D1-like activation (D1 and D5) can be excitation (via opening of sodium channels) or inhibition (via opening of potassium channels); the ultimate effect of D2-like activation (D2, D3, and D4) is usually inhibition of the target neuron. Consequently, it is incorrect to describe dopamine itself as either excitatory or inhibitory: its effect on a target neuron depends on which types of receptors are present on the membrane of that neuron and on the internal responses of that neuron to the second messenger cAMP. D1 receptors are the most numerous dopamine receptors in the human nervous system; D2 receptors are next; D3, D4, and D5 receptors are present at significantly lower levels.",
            "score": 360.1203918457031
        },
        {
            "docid": "57441533_5",
            "document": "D. James Surmeier . By mid-90s, despite widespread consensus regarding the clinical relevance of striatal dopaminergic signaling, the distribution and seggregation of different classes of dopamine receptors, into either the same or distinct neuronal populations was unclear and remained widely debated. In pioneering experiments, using patch clamp recordings in conjunction with single cell gene profiling through RT-PCR, Surmeier reconciled the seemingly confounding results from anatomical and functional studies by showing that the direct (striatonigral) and indirect pathway (striatopallidal) striatal projection neurons predominantly expressed either the D1 or D2 dopamine receptors. Following this discovery, using pharmacology and spike-timing-dependent plasticity (STDP) protocols in genetically identified D1 or D2 receptor expressing neurons, Surmeier elucidated the distinct roles played by both the receptors in the induction of long-term potentiation and depression at the cortico-striatal synapses. Simultaneously, he also showed that in projection neurons that do not express the D2 receptors, synaptic depression dependent on D2 receptor activation is mediated by D2 receptors in cholinergic neurons, M1 muscarinic receptor activation resulting in reduced calcium channel, CaV1.3 opening in projection neurons and endocannabinoid signaling. Understanding the opposing effects of D1 and D2 receptor signaling and the consequent insights into the dopaminergic modulation of bi-directional synaptic plasticity in the direct and indirect spiny neurons was a conceptual advance that has proven fundamental to understanding striatal function in both behavioral adaptation as well as Parkinson's disease pathology, and continues to provide a foundation for current models of how dopamine controls striatal circuitry.",
            "score": 352.02728271484375
        },
        {
            "docid": "35822485_17",
            "document": "Epigenetics of cocaine addiction . Zhang et al. had previously seen that chronic cocaine administration leads to increased dendritic branching and spine density on medium spine neurons and prefrontal cortex pyramidal neurons, which may contribute to cocaine-induced neuroadaptations. When investigating the genes that were receptors and modulators, they found that expression of the sigma 1 receptor and \"RGS4\" was not upregulated after repeat cocaine administration in DA D1 receptor mutants, suggesting functional dopamine D1 receptor is necessary for their induction. This receptor had been seen to modulate the rewarding effects of cocaine, and receptor antagonists had blocked the acute locomotor stimulating effect and lowered behavioral sensitization. Changes in the sigma 1 receptor have been shown to modulate dopamine release, so shifts in its expression can change the behavioral responses to cocaine with pre and post synaptic influences. They knew that \"RGS4\" proteins can modulate G-protein-coupled receptor function, and since \"RGS4\" levels can increase or decrease in response to D1/D2 receptor stimulation it could be involved in alterations of the signal transduction pathway after D1 receptor activation from repeat cocaine stimulation.",
            "score": 326.2458190917969
        },
        {
            "docid": "1662513_4",
            "document": "Relapse . The availability of the dopamine receptor D2 plays a role in self-administration and the reinforcing effects of cocaine and other stimulants. The D2 receptor availability has an inverse relationship to vulnerability to the reinforcing effects of the drug. That is, as D2 receptors become limited the user becomes more susceptible to the reinforcing effects of cocaine. It is currently unknown if a predisposition to low D2 receptor availability is possible; however, most studies support the idea that changes in D2 receptor availability are a result, rather than a precursor, of cocaine use. It has also been noted that D2 receptors may return to the level existing prior to drug exposure during long periods of abstinence, a fact which may have implications in relapse treatment.",
            "score": 319.66912841796875
        },
        {
            "docid": "14131548_4",
            "document": "Dopamine receptor D1 . The D subtype of the dopamine receptor is the most abundant dopamine receptor in the central nervous system. This G-protein coupled receptor is Gs/a coupled and indirectly activates cyclic AMP-dependent protein kinase, stimulating the neuron. D receptors regulate neuronal growth and development, mediate some behavioral responses, and modulate dopamine receptor D-mediated events. Alternative transcription initiation sites result in two transcript variants of the gene. D1-D2 dopamine receptor heteromer formation is observed.",
            "score": 316.5921630859375
        },
        {
            "docid": "148980_20",
            "document": "Chlorpromazine . Chlorpromazine is a very effective antagonist of D2 dopamine receptors and similar receptors, such as D3 and D5. Unlike most other drugs of this genre, it also has a high affinity for D1 receptors. Blocking these receptors causes diminished neurotransmitter binding in the forebrain, resulting in many different effects. Dopamine, unable to bind with a receptor, causes a feedback loop that causes dopaminergic neurons to release more dopamine. Therefore, upon first taking the drug, patients will experience an increase in dopaminergic neural activity. Eventually, dopamine production of the neurons will drop substantially and dopamine will be removed from the synaptic cleft. At this point, neural activity decreases greatly; the continual blockade of receptors only compounds this effect.",
            "score": 305.217529296875
        },
        {
            "docid": "8582684_9",
            "document": "Reward system . Most of the dopamine pathways (i.e., neurons that use the neurotransmitter dopamine to communicate with other neurons) that project out of the ventral tegmental area are part of the reward system; in these pathways, dopamine acts on D1-like receptors or D2-like receptors to either stimulate (D1-like) or inhibit (D2-like) the production of cAMP. The GABAergic medium spiny neurons of the striatum are components of the reward system as well. The glutamatergic projection nuclei in the subthalamic nucleus, prefrontal cortex, hippocampus, thalamus, and amygdala connect to other parts of the reward system via glutamate pathways. The medial forebrain bundle, which is a set of many neural pathways that mediate brain stimulation reward (i.e., reward derived from direct electrochemical stimulation of the lateral hypothalamus), is also a component of the reward system.",
            "score": 300.05889892578125
        },
        {
            "docid": "5690382_3",
            "document": "Medium spiny neuron . Direct pathway MSNs excite their ultimate basal ganglia output structure (e.g., the thalamus) and promote associated behaviors; these neurons express D1-type dopamine receptors, adenosine A1 receptors, dynorphin peptides, and substance P peptides. Indirect pathway MSNs inhibit their output structure and in turn inhibit associated behaviors; these neurons express D2-type dopamine receptors, adenosine A2A receptors (A2A), heterotetramers, and enkephalin. Both types express glutamate receptors (NMDAR and AMPAR), cholinergic receptors (M1 and M4) and CB1 receptors are expressed on the somatodendritic area of both MSN types. A subpopulation of MSNs contain both D1-type and D2-type receptors, with approximately\u00a040% of striatal MSNs expressing both DRD1 and DRD2 mRNA. In the nucleus accumbens (NAcc), these mixed-type MSNs that contain both D1-type and D2-type receptors are mostly contained in the NAcc shell.",
            "score": 283.05694580078125
        },
        {
            "docid": "48548_62",
            "document": "Dopamine . Nausea and vomiting are largely determined by activity in the area postrema in the medulla of the brainstem, in a region known as the chemoreceptor trigger zone. This area contains a large population of type D2 dopamine receptors. Consequently, drugs that activate D2 receptors have a high potential to cause nausea. This group includes some medications that are administered for Parkinson's disease, as well as other dopamine agonists such as apomorphine. In some cases, D2-receptor antagonists such as metoclopramide are useful as anti-nausea drugs.",
            "score": 282.38262939453125
        },
        {
            "docid": "57257625_9",
            "document": "Antipsychotic switching . Antipsychotics work by antagonizing the dopamine receptor D2 (D2R) in the mesolimbic pathway of the brain. When the D2R is suppressed, the neurons may become sensitized to the effect of an endogenous ligand (i.e. dopamine) by up-regulating the production of postsynaptic D2Rs. If the D2 receptors are not subsequently suppressed at previous levels after an abrupt discontinuation of an antipsychotic (e.g. after switching to weak D2R antagonists quetiapine or clozapine), a rebound/supersensitivity psychosis may occur due to the overwhelming effect of endogenous dopamine on sensitized neurons. Supersensitivity psychosis, also called rapid-onset psychosis, must be distinguished from a relapse or exacerbation of the underlying disease (e.g. schizophrenia). Supersensitivity psychosis generally occurs around 6 weeks after an oral antipsychotic is discontinued, or 3 months after a LAI antipsychotic is discontinued. In addition, supersensitivity psychosis is generally easier to reverse by reintroducing D2R antagonism (i.e. restarting the discontinued drug), whereas a relapsed schizophrenia is more difficult to control.",
            "score": 280.2122802734375
        },
        {
            "docid": "737439_12",
            "document": "Dopamine receptor . D1 receptor agonism and D2 receptor blockade also increases mRNA translation by phosphorylating ribosomal protein s6, resulting in activation of mTOR. The behavioral implications are unknown. Dopamine receptors may also regulate ion channels and BDNF independent of cAMP, possibly through direct interactions. There is evidence that D1 receptor agonism regulates phospholipase C independent of cAMP, however implications and mechanisms remain poorly understood. D2 receptor signaling may mediate protein kinase B, arrestin beta 2, and GSK-3 activity, and inhibition of these proteins results in stunting of the hyperlocomotion in amphetamine treated rats. Dopamine receptors can also transactivate Receptor tyrosine kinases.",
            "score": 280.0729064941406
        },
        {
            "docid": "24514_42",
            "document": "Psychosis . The connection between dopamine and psychosis is generally believed complex. While dopamine receptor D2 suppresses adenylate cyclase activity, the D1 receptor increases it. If D2-blocking drugs are administered the blocked dopamine spills over to the D1 receptors. The increased adenylate cyclase activity affects genetic expression in the nerve cell, which takes time. Hence antipsychotic drugs take a week or two to reduce the symptoms of psychosis. Moreover, newer and equally effective antipsychotic drugs actually block slightly less dopamine in the brain than older drugs whilst also blocking 5-HT2A receptors, suggesting the 'dopamine hypothesis' may be oversimplified. Soyka and colleagues found no evidence of dopaminergic dysfunction in people with alcohol-induced psychosis and Zoldan et al. reported moderately successful use of ondansetron, a 5-HT receptor antagonist, in the treatment of levodopa psychosis in Parkinson's disease patients.",
            "score": 279.9625244140625
        },
        {
            "docid": "44113647_7",
            "document": "Lomerizine . While some calcium-channel blockers, such as flunarizine, act on the dopaminergic system, lomerizine is ineffective \"in vivo\" at inhibiting the release of dopamine. However, it has been observed to weakly inhibit the binding of [H]spiperone to D2 dopamine receptors \"in vitro\". While researchers are unsure of the reason for this difference, one hypothesis is that the doses administered cannot reach a high enough concentration in the brain to affect D2 receptors.",
            "score": 279.22125244140625
        },
        {
            "docid": "50760491_9",
            "document": "Nancy Zahniser . Zahniser examined the pharmacological effects of cocaine usage on the brain in rodents, and used her findings to create a model for human cocaine abuse. Her experiments using autoradiography revealed cocaine's effect on D1 and D2 dopamine receptors in the rat striatum. Rats treated with cocaine eight times in one 24-hour period showed increased responsiveness and a temporary artificial elevation of D2 receptors in the nucleus accumbens over a 7-day period. The findings showed a correlation between cocaine administration and behavioral sensitization, thus providing a premise for addiction in human cocaine users.",
            "score": 279.104248046875
        },
        {
            "docid": "37691875_20",
            "document": "Addiction-related structural neuroplasticity . Exposure to drugs of abuse elicits LTP at excitatory synapses on VTA dopamine neurons. Excitatory synapses in brain slices from the VTA taken 24 hours after a single cocaine exposure showed an increase in AMPA receptors in comparison to a saline control. Additional LTP could not be induced in these synapses. This is thought to be because the maximal amount of LTP had already been induced by the administration of cocaine. LTP is only seen on the dopamine neurons, not on neighboring GABAergic neurons. This is of interest because the administration of drugs of abuse increases the excitation of VTA dopamine neurons, but does not increase inhibition. Excitatory inputs into the VTA will activate the dopamine neurons 200%, but do not increase activation of GABA neurons which are important in local inhibition.",
            "score": 278.1994934082031
        },
        {
            "docid": "14022657_4",
            "document": "Dopamine receptor D2 . In mice, regulation of D2R surface expression by the neuronal calcium sensor-1 (NCS-1) in the dentate gyrus is involved in exploration, synaptic plasticity and memory formation. A recent study has shown a potential role for D2R in retrieval of fear memories in the prelimbic cortex.",
            "score": 277.6881408691406
        },
        {
            "docid": "18203126_4",
            "document": "Tetrahydropalmatine . The pharmacological profile of l-THP includes antagonism of dopamine D1, and D2 receptors as well as actions at dopamine D3, alpha adrenergic and serotonin receptors. The Ki values for l-THP at D1 and D2 dopamine receptors are approximately 124 nM (D1) and 388 nM (D2). In addition to the antagonism of post-synaptic dopamine receptors, the blockade of pre-synaptic autoreceptors by l-THP results in increased dopamine release, and it has been suggested that lower affinity of l-THP for D2 receptors may confer some degree of autoreceptor selectivity. Along with dopamine receptors, l-THP has been reported to interact with a number of other receptor types, including alpha-1 adrenergic receptors, at which it functions as an antagonist, and GABA-A receptors, through positive allosteric modulation. Additionally, l-THP displays significant binding to 5-HT1A and alpha-2 adrenergic receptors. In the case of 5-HT1A receptors, l-THP binds with a Ki of approximately 340 nM.",
            "score": 275.7762451171875
        },
        {
            "docid": "50165247_3",
            "document": "Cortico-striatal-thalamic-cortical loop . The striatum modulates the GPi and the SNr via two pathways: one direct and one indirect. These pathways begin with GABA-ergic medium spiny neurons (MSNs). MSNs are the main neuron that makes up the human striatum. D1 dopamine receptor modulated MSNs send GABAergic inhibitory projections directly to the globus pallidus interna (GPi). D2 dopamine receptor modulated MSNs send GABAergic inhibitory projections to the GPe. The GPe sends GABAergic inhibitory inputs to the subthalamic nucleus (STN), which provides excitatory dopaminergic input to the GPe and the SNr. D1 receptor signaling increases dendritic excitability of MSNs, while D2 receptor signaling decreases dendritic excitability of striatopallidal MSNs.",
            "score": 275.144775390625
        },
        {
            "docid": "27790_28",
            "document": "Schizophrenia . Particular attention has been paid to the function of dopamine in the mesolimbic pathway of the brain. This focus largely resulted from the accidental finding that phenothiazine drugs, which block dopamine function, could reduce psychotic symptoms. It is also supported by the fact that amphetamines, which trigger the release of dopamine, may exacerbate the psychotic symptoms in schizophrenia. The influential dopamine hypothesis of schizophrenia proposed that excessive activation of D receptors was the cause of (the positive symptoms of) schizophrenia. Although postulated for about 20\u00a0years based on the D blockade effect common to all antipsychotics, it was not until the mid-1990s that PET and SPET imaging studies provided supporting evidence. While dopamine D2/D3 receptors are elevated in schizophrenia, the effect size is small, and only evident in medication naive schizophrenics. On the other hand, presynaptic dopamine metabolism and release is elevated despite no difference in dopamine transporter. The altered synthesis of dopamine in the nigrostriatal system have been confirmed in several human studies. Hypoactivity of dopamine D1 receptor activation in the prefrontal cortex has also been observed. The hyperactivity of D2 receptor stimulation and relative hypoactivity of D1 receptor stimulation is thought to contribute to cognitive dysfunction by disrupting signal to noise ratio in cortical microcircuits. The dopamine hypothesis is now thought to be simplistic, partly because newer antipsychotic medication (atypical antipsychotic medication) can be just as effective as older medication (typical antipsychotic medication), but also affects serotonin function and may have slightly less of a dopamine blocking effect.",
            "score": 274.85101318359375
        },
        {
            "docid": "553317_12",
            "document": "Nucleus accumbens . Cell types: Neurons in the nucleus accumbens are mostly medium spiny neurons (MSNs) containing mainly D1-type (i.e., DRD1 and DRD5) or D2-type (i.e., DRD2, DRD3, and DRD4) dopamine receptors. A subpopulation of MSNs contain both D1-type and D2-type receptors, with approximately\u00a040% of striatal MSNs expressing both DRD1 and DRD2 mRNA. These mixed-type NAcc MSNs with both D1-type and D2-type receptors are mostly confined to the NAcc shell. The neurons in the shell, as compared to the core, have a lower density of dendritic spines, less terminal segments, and less branch segments than those in the core. The shell neurons project to the subcommissural part of the ventral pallidum as well as the ventral tegmental area and to extensive areas in the hypothalamus and extended amygdala.",
            "score": 274.7373962402344
        },
        {
            "docid": "12099822_2",
            "document": "Dopexamine . Dopexamine is a synthetic analogue of dopamine that is administered intravenously in hospitals to reduce exacerbations of heart failure and to treat heart failure following cardiac surgery. It is not used often, as more established drugs like epinephrine, dopamine, dobutamine, norepinephrine, and levosimendan work as well. It works by stimulating beta-2 adrenergic receptors and peripheral dopamine receptor D1 and dopamine receptor D2. It also inhibits of neuronal re-uptake of norepinephrine",
            "score": 273.5619201660156
        },
        {
            "docid": "38468_27",
            "document": "Psilocybin . Psilocybin is rapidly dephosphorylated in the body to psilocin, which is a partial agonist for several serotonin receptors, which are also known as 5-hydroxytryptamine (5-HT) receptors. Psilocin has a high affinity for the 5-HT and 5-HT receptors in the human brain, and with a slightly lower affinity for the 5-HT receptor. Psilocin binds with low affinity to 5-HT1 receptors, including 5-HT and 5-HT. Serotonin receptors are located in numerous parts of the brain, including the cerebral cortex, and are involved in a wide range of functions, including regulation of mood and motivation. The psychotomimetic (psychosis-mimicking) effects of psilocin can be blocked in a dose-dependent fashion by the 5-HT antagonist drug ketanserin. Various lines of evidence have shown that interactions with non-5-HT receptors also contribute to the subjective and behavioral effects of the drug. For example, psilocin indirectly increases the concentration of the neurotransmitter dopamine in the basal ganglia, and some psychotomimetic symptoms of psilocin are reduced by haloperidol, a non-selective dopamine receptor antagonist. Taken together, these suggest that there may be an indirect dopaminergic contribution to psilocin's psychotomimetic effects. Unlike LSD, which binds to D2-like dopamine receptors in addition to having strong affinity for several 5-HT receptors, psilocybin and psilocin have no affinity for the dopamine D2 receptors.",
            "score": 272.68359375
        },
        {
            "docid": "14022657_5",
            "document": "Dopamine receptor D2 . In flies, activation of the D autoreceptor protected dopamine neurons from cell death induced by MPP+, a toxin mimicking Parkinson's disease pathology.",
            "score": 271.78387451171875
        },
        {
            "docid": "21865_25",
            "document": "Neurotransmitter . Drugs targeting the neurotransmitter of major systems affect the whole system, which can explain the complexity of action of some drugs. Cocaine, for example, blocks the re-uptake of dopamine back into the presynaptic neuron, leaving the neurotransmitter molecules in the synaptic gap for an extended period of time. Since the dopamine remains in the synapse longer, the neurotransmitter continues to bind to the receptors on the postsynaptic neuron, eliciting a pleasurable emotional response. Physical addiction to cocaine may result from prolonged exposure to excess dopamine in the synapses, which leads to the downregulation of some post-synaptic receptors. After the effects of the drug wear off, an individual can become depressed due to decreased probability of the neurotransmitter binding to a receptor. Fluoxetine is a selective serotonin re-uptake inhibitor (SSRI), which blocks re-uptake of serotonin by the presynaptic cell which increases the amount of serotonin present at the synapse and furthermore allows it to remain there longer, providing potential for the effect of naturally released serotonin. AMPT prevents the conversion of tyrosine to L-DOPA, the precursor to dopamine; reserpine prevents dopamine storage within vesicles; and deprenyl inhibits monoamine oxidase (MAO)-B and thus increases dopamine levels.",
            "score": 270.4542541503906
        },
        {
            "docid": "14022657_7",
            "document": "Dopamine receptor D2 . The long form (D2Lh) has the \"canonical\" sequence and functions as a classic post-synaptic receptor. The short form (D2Sh) is pre-synaptic and functions as an autoreceptor that regulates the levels of dopamine in the synaptic cleft. Agonism of D2sh receptors inhibits dopamine release; antagonism increases dopaminergic release. A third D2(Longer) form differs from the canonical sequence where 270V is replaced by VVQ.",
            "score": 268.77911376953125
        },
        {
            "docid": "5690382_2",
            "document": "Medium spiny neuron . Medium spiny neurons (MSNs), also known as spiny projection neurons, are a special type of GABAergic inhibitory cell representing 95% of neurons within the human striatum, a basal ganglia structure. Medium spiny neurons have two primary phenotypes (characteristic types): D1-type MSNs of the direct pathway and D2-type MSNs of the indirect pathway. Most striatal MSNs contain only D1-type or D2-type dopamine receptors, but a subpopulation of MSNs exhibit both phenotypes.",
            "score": 268.70501708984375
        },
        {
            "docid": "23753743_13",
            "document": "Biology of obsessive\u2013compulsive disorder . Reduced dopamine D1 receptor (D1) and dopamine D2 receptor (D2) have been reported in the striatum in people with OCD, along with both increased and decreased reports of dopamine transporter (DAT) binding. While antipsychotics are sometimes used to treat refractory OCD, they frequently fail in treating or exacerbate OCD symptoms. Furthermore psychotimulants are sometimes used to treat OCD. Treatment with deep brain stimulation is effective in OCD, and response correlates with increased dopamine in the nucleus accumbens. Combined this evidence suggests that OCD may be associated with both increased and decreased dopamine signaling, or that a unidirectional model may not be adequate.",
            "score": 268.55572509765625
        },
        {
            "docid": "1846451_12",
            "document": "Dopamine transporter . Staining in the striatum and nucleus accumbens of the mesolimbic pathway was dense and heterogeneous. In the striatum, DAT is localized in the plasma membrane of axon terminals. Double immunocytochemistry demonstrated DAT colocalization with two other markers of nigrostriatal terminals, tyrosine hydroxylase and D2 dopamine receptors. The latter was thus demonstrated to be an autoreceptor on cells that release dopamine. TAAR1 is a presynaptic intracellular receptor that is also colocalized with DAT and which has the opposite effect of the D2 autoreceptor when activated; i.e., it internalizes dopamine transporters and induces efflux through reversed transporter function via PKA and PKC signaling.",
            "score": 265.86236572265625
        },
        {
            "docid": "3327510_12",
            "document": "Cinnarizine . In addition to antagonizing D2 receptors, treatment with cinnarizine has also been shown to lead to reduced presynaptic dopamine and serotonin, as well as alterations in vesicular transport of dopamine. Terland et al. have shown that chronic treatment with cinnarizine builds the drug concentrations high enough that they interfere with the proton electrochemical gradient necessary for packaging dopamine into vesicles. Cinnarizine, pKa = 7.4, acts as a protonophore, which prevents the MgATP-dependent production of the electrochemical gradient crucial to the transport and storage of dopamine into vesicles, and thereby lowers the levels of dopamine in the basal ganglia neurons and leads to the Parkinson's symptoms.",
            "score": 265.822021484375
        },
        {
            "docid": "148980_23",
            "document": "Chlorpromazine . Chlorpromazine and other typical antipsychotics are primarily blockers of D2 receptors. In fact an almost perfect correlation exists between the therapeutic dose of a typical antipsychotic and the drug's affinity for the D2 receptor. Therefore, a larger dose is required if the drug\u2019s affinity for the D2 receptor is relatively weak. A correlation exists between average clinical potency and affinity of the antipsychotics for dopamine receptors. Chlorpromazine tends to have greater effect at serotonin receptors than at D2 receptors, which is notably the opposite effect of the other typical antipsychotics. Therefore, chlorpromazine with respect to its effects on dopamine and serotonin receptors is more similar to the atypical antipsychotics than to the typical antipsychotics.",
            "score": 265.4515075683594
        },
        {
            "docid": "35822485_16",
            "document": "Epigenetics of cocaine addiction . Also involved in the CREB-Fos protein pathways is the dopamine D1 receptor (DRD1), expressed in neurons in the nucleus accumbens and caudate putamen regions. Zhang et al. focused on this receptor, as it is known to mediate the effects of cocaine. When stimulated, it increases cAMP levels, in turn leading to CREB activation. They had observed previous cocaine injections led to a direct increase in D1 receptor sensitivity. Through lines of D1 receptor mutant mice it had also been implicated in mediating both the locomotor sensation and rewarding effects of cocaine. Acute cocaine injections induced c-fos and CREB expression via D1 receptors and repeat cocaine administration, which associated with long lasting AP-1 transcription complexes containing \u0394FosB. Persistent \u0394FosB expression in D1 receptors in nucleus accumbens led to a significant increase in the locomotor-stimulating and rewarding effects of cocaine. Conversely, an increase of CREB was shown to decrease the rewarding effects of cocaine.  Zhang et al. also used microarrays to identify specific genes induced by chronic cocaine use, which depend on a functional D1 receptor 24\u00a0hours after cocaine withdrawal. There were 109 genes identified that were either up or down regulated by 1.2 fold or more in the caudate putamen D1 receptor mutant mice after repeat injections. The expression of these genes was totally normal in mice with functional D1 receptors, suggesting chronic cocaine use had a direct influence on mediating these genes through a functional DRD1 receptor They found genes belonging to a number of functional groups, and chose six candidate genes from three of these functional groups to verify their differential expression in the caudate putamen. For each gene, researchers verified dependency of their expression on the D1 receptor after cocaine treatment using Trichostatin A or other receptor antagonists. Specifically, they focused on the genes encoding extracellular factors, receptors, modulators, and intracellular signaling molecules. These can be regulated by chronic cocaine treatment via D1 receptors, and all of the genes contain AP-1 transcriptional complex binding sites in their promoter regions. For extracellular signaling molecules, they looked at expression of the genes IGFBP6 and SDF1. Both of these were induced in the caudate putamen in wild type mice, but attenuated in the D1 receptor mutants. This suggests that IGFBP6 and SDF1 can be induced by repeat cocaine administration, and also that this interaction is partially dependent on a functional D1 receptor.",
            "score": 264.9841003417969
        },
        {
            "docid": "44517156_5",
            "document": "Dopamine therapy . In patients with schizophrenia, evidence indicates abnormal dopamine receptor D2 structure, as well as a reduced link between dopamine receptor D1 and receptor D2. Studies have shown that targeting the D1 receptors in the prefrontal cortex can improve the cognitive functioning of schizophrenic patients. However, adverse effects of dopamine therapy may occur, including difficulty with impulse control. More research is needed to fully understand the effects of dopamine therapy in patients suffering from schizophrenia.",
            "score": 264.7699279785156
        }
    ]
}